Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cedaraniline plus PD-1 antibody (C-P regimen) in relapsed T-cell acute lymphoblastic leukemia/lymphoma after allogeneic HSCT
ChiCTR2000041076Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cedaraniline in acute lymphoblastic leukemia (ALL), lymphoma and Relapse of disease after allogeneic hematopoietic stem cell transplantation, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Safety and Overall survival. Started Jan 2021; status: recruiting.
02
Drugs
cedaraniline
03
Conditions
acute lymphoblastic leukemia (ALL)lymphomaRelapse of disease after allogeneic hematopoietic stem cell transplantation
Beyond the preview
Go deeper on ChiCTR2000041076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041076.